Description:

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02416206

Link:

https://clinicaltrials.gov/show/NCT02416206

Keywords:
Versions (1) ▾
  1. 5/15/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

May 15, 2019

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT02416206

Eligibility Multiple Myeloma NCT02416206

Inclusion Criteria
age between 18 - 70 years
karnofsky status ≥ 70%
diagnosis of multiple myeloma
within 9 months of the start of induction chemotherapy and no evidence of relapse or progression.
availability of cryopreserved peripheral blood stem cells with a cd34 dose of at least 2x106/kg.
Exclusion Criteria
poor cardiac function: left ventricular ejection fraction <40%
poor pulmonary function: fev1, fvc, or dlco <40% predicted
poor liver function: bilirubin >2.5 mg/dl (not due to hemolysis, gilbert's or primary malignancy), ast/alt > 3x uln
poor renal function: creatinine >2.0 mg/dl or creatinine clearance < 40 ml/min (calculated creatinine clearance is permitted)
ongoing or active systemic infection, active hepatitis b or c virus infection, or known human immunodeficiency virus (hiv) positive.
women of childbearing potential who currently are pregnant or who are not practicing adequate contraception
patients who have any debilitating medical or psychiatric illness which would preclude their giving informed consent or their receiving optimal treatment and follow-up.